The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A real-world clinicogenomic study of androgen receptor mutations and co-mutations in prostate cancer: Clinical implications.
 
Emma Sturgill
Employment - Sarah Cannon Research Institute
Stock and Other Ownership Interests - HCA Healthcare; McKesson/US Oncology Network
 
Daniel Luckett
Employment - HCA Healthcare; McKesson
Stock and Other Ownership Interests - HCA Healthcare; McKesson
Consulting or Advisory Role - Sanofi (I)
 
Tarun Agrawal
Employment - McKesson
Travel, Accommodations, Expenses - McKesson
 
Jordan Best
No Relationships to Disclose
 
Rikki Williams
Employment - HCA Healthcare; HCA Healthcare (I)
Travel, Accommodations, Expenses - HCA Healthcare
 
Manojkumar Bupathi
Honoraria - Agendia; AIQ Solutions; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; EMD Serono; Exelixis; Exelixis; Exelixis; Exelixis; Janssen; Myovant Sciences; Pfizer
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Exelixis
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Pfizer
 
Mark Fleming
Consulting or Advisory Role - Novartis
 
Ian Schnadig
Employment - Compass Oncology
Leadership - Compass Oncology
 
Vivek Subbiah
Consulting or Advisory Role - AADi; Abbvie (Inst); Bayer (Inst); Foundation Medicine; Illumina; Incyte (Inst); Loxo/Lilly; Novartis (Inst); Pfizer (Inst); Pheon Therapeutics (Inst); Relay Therapeutics (Inst); Roche (Inst)
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Relay Therapeutics (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Other Relationship - Clinical Care Options; Medscape
 
David Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Jazz Pharmaceuticals (Inst); Lyell Immunopharma (Inst); MedImmune (Inst); ModeX Therapeutics (Inst); Novartis (Inst); Novocure (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Ascendis Pharma (Inst); Asher Biotherapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); EMD Serono (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); Faeth Therapeutics (Inst); Foundation Bio (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Lyell Immunopharma (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Molecular Templates (Inst); Monte Rosa Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncologie (Inst); Peloton Therapeutics (Inst); Phanes Therapeutics (Inst); PTC Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Seagen (Inst); Shenzhen Chipscreen Biosciences (Inst); Stemline Therapeutics (Inst); Strata Oncology (Inst); Synthekine (Inst); Taiho Oncology (Inst); Takeda (Inst); Tango Therapeutics (Inst); Tango Therapeutics (Inst); Tarveda Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Verastem (Inst); Zai Lab (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
Howard Burris
Employment - Sarah Cannon Research Institute
Leadership - Sarah Cannon Research Institute; Torl Biotherapeutics
Stock and Other Ownership Interests - HCA Healthcare
Consulting or Advisory Role - AstraZeneca (Inst); Bicycle Therapeutics (Inst); GRAIL (Inst); Incyte (Inst); Roche (Inst); Vincerx Pharma (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); Archer (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arvinas (Inst); AstraZeneca (Inst); BioAtla (Inst); Bristol-Myers Squibb (Inst); CALGB (Inst); Celgene (Inst); Coordination Pharmaceuticals (Inst); CytomX Therapeutics (Inst); EMD Serono (Inst); Foundation Medicine (Inst); Gossamer Bio (Inst); Harpoon therapeutics (Inst); Hengrui Therapeutics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kymab (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Takeda/Millennium (Inst); Tesaro (Inst); TG Therapeutics (Inst); Verastem (Inst); Vertex (Inst); XBiotech (Inst); Zymeworks (Inst)
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb (Inst)
 
Andrew McKenzie
Employment - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
 
Benjamin Garmezy
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); crispr therapeutics (Inst); Eikon Therapuetics (Inst); Envision Pharma Group (Inst); Exelixis (Inst); Flare Therapeutics (Inst); Genentech (Inst); Harbour BioMed (Inst); IDEAYA Biosciences (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kineta (Inst); Kinnate Biopharma (Inst); Loxo (Inst); Loxo/Lilly (Inst); MiNK Therapeutics (Inst); Nuvation Bio (Inst); ProfoundBio (Inst); Roche/Genentech (Inst); Takeda (Inst); Teon Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Xencor (Inst); Zenshine (Inst); Zenshine (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Adaptimmune (Inst); Adicet Bio (Inst); AIQ Global (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Exelixis (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Rondo Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Xencor (Inst)